H1 results were in line, with IV iron drug Ferinject leading the pack – driven by better patient access with the easing of restrictions. Nephrology was a mixed bag as the strong demand for Velphoro was offset by COVID-19-related headwinds in the ESA portfolio. Veltassa was still a drag, given the reimbursement hurdles. Notably, FY21 guidance has been reiterated and the new CEO has a rich launch pipeline ahead. Given the robust balance sheet, business development activities can’t be ruled out.
05 Aug 2021
Ferinject’s outperformance pulled down by Mircera and Veltassa; FY21 outlook confirmed
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Ferinject’s outperformance pulled down by Mircera and Veltassa; FY21 outlook confirmed
- Published:
05 Aug 2021 -
Author:
Sumit Sayal -
Pages:
4
H1 results were in line, with IV iron drug Ferinject leading the pack – driven by better patient access with the easing of restrictions. Nephrology was a mixed bag as the strong demand for Velphoro was offset by COVID-19-related headwinds in the ESA portfolio. Veltassa was still a drag, given the reimbursement hurdles. Notably, FY21 guidance has been reiterated and the new CEO has a rich launch pipeline ahead. Given the robust balance sheet, business development activities can’t be ruled out.